Reviewing NewAmsterdam Pharma (NASDAQ:NAMS) and Kaya (OTCMKTS:KAYS)

NewAmsterdam Pharma (NASDAQ:NAMS) and Kaya (OTCMKTS:KAYS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Volatility & Risk

NewAmsterdam Pharma has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500. Comparatively, Kaya has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.

Institutional and Insider Ownership

89.9% of NewAmsterdam Pharma shares are held by institutional investors. 19.5% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 23.5% of Kaya shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares NewAmsterdam Pharma and Kaya”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$45.56 million	56.42	-$176.94 million	($2.60)	-9.00
Kaya	$200,000.00	4.43	$1.61 million	($0.08)	-0.50

Kaya has lower revenue, but higher earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Kaya, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for NewAmsterdam Pharma and Kaya, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	0	0	6	0	3.00
Kaya	0	0	0	0	0.00

NewAmsterdam Pharma currently has a consensus target price of $43.33, suggesting a potential upside of 85.11%. Given NewAmsterdam Pharma’s stronger consensus rating and higher possible upside, research analysts plainly believe NewAmsterdam Pharma is more favorable than Kaya.

Profitability

This table compares NewAmsterdam Pharma and Kaya’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	N/A	N/A	N/A
Kaya	N/A	-9.79%	-1,143.19%

Summary

NewAmsterdam Pharma beats Kaya on 8 of the 13 factors compared between the two stocks.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

About Kaya

Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, engages in the operation of psychedelic treatment clinics and medical cannabis dispensaries primarily in the United States. It offers a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. The company also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, it is involved in the development of a psychedelic treatment center under The Sacred Mushroom name, that provides its guests access to psilocybin treatments, located in Portland, Oregon. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. is headquartered in Fort Lauderdale, Florida.